A Patient-Doctor Bond Forged in Fighting Follicular Lymphoma | Dana-Farber Cancer Institute
Along with his wife, Lorna, one individual has been there for Robert Jenkins nearly every step of the way: his oncologist Eric Jacobsen, MD.
Along with his wife, Lorna, one individual has been there for Robert Jenkins nearly every step of the way: his oncologist Eric Jacobsen, MD.
Journal of Neuro-Oncology – Glioblastoma is a malignant brain tumor with a poor prognosis. Genetic mutations associated with this disease are complex are not fully…
This segment of the virtual tumor board presentation focuses on the clinical development and use of emerging therapies, specifically Belumosudil, for the management of chronic…
Joseph G. Jurcic, MD, discusses the use of JAK inhibitors in the management of myelofibrosis.
AbstractPancreatic ductal adenocarcinoma (PDAC) therapeutic resistance is largely attributed to a unique tumor microenvironment embedded with an abundance of cancer-associated fibroblasts (CAF). Distinct CAF populations…
Raajit K. Rampal, MD, PhD, discusses choosing among JAK inhibitors based on specific patient needs, such as platelet counts and anemia, emphasizing the importance of…
AbstractThe tumor microenvironment (TME) profoundly influences tumorigenesis, with gene expression in the breast TME capable of predicting clinical outcomes. The TME is complex and includes…
Knowing what symptoms to look for can help your doctor find cancer early when it’s most treatable.
Hyunseok Kang, MD, discusses the importance of balancing toxicities and other factors when initiating first-line treatments for patients with refractory differentiated thyroid cancer (DTC), while…
Matthew Lunning, DO, FACP, discusses the use of CAR T-cell therapy lisocabtagene maraleucel in the second-line setting for patients with B-cell lymphoma.
Abstract. Serine metabolism plays a pivotal role in cancer, making it an appealing therapeutic target. Two recent studies published in Nature Metabolism and Science Translational…